STUDY OF FUNCTIONAL AND STRUCTURAL OUTCOMES OF INTRAVITREAL BEVACIZUMAB IN MACULAR EDEMA SECONDARY TO RETINAL VENOUS OCCLUSIVE DISEASES

Abstract

Background: Retinal vein occlusions (RVOs) are the second most common form of retinal vascular disease with an estimated 15-year cumulative incidence in adults of 2.3%. Bevacizumab is an off label anti-VEGF drug used widely in the management of diabetic macular edema and other retinal vascular disorders. Present study was aimed to study functional and structural outcomes of intravitreal bevacizumab in macular edema secondary to retinal venous occlusive diseases. Material and Methods: Present study was single center, Prospective clinical interventional study conducted patients with macular edema secondary to retinal venous occlusive disease with a central macular thickness > 250µ on OCT with a duration of <3 months.